New Mexico Mesothelioma Fact Sheet
While mesothelioma is a problem in all states, the specific incident rate for New Mexico is 0.8 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in NM, recent NM mesothelioma-related court cases, mesothelioma specialists in NM and potential asbestos hotspots in New Mexico.
New Mexico Mesothelioma Info
By clicking on the above tabs, you will find information on mesothelioma specific to the state of New Mexico
New Mexico Research and Clinical Trials
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
New Mexico Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
New Mexico Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
New Mexico Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
New Mexico Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
Hospitals and Cancer Centers
We do not have any doctors or cancer centers for this state at the moment.
We do not have any doctors or cancer centers for this state at the moment.
| City | Site |
| Albuquerque |
Associates Food Services Coronado Center |
| Albuquerque |
New Mexico Power Plant Park Plaza University of New Mexico Western Skies Hotel |
| Albuquerque City |
Albuquerque City Auditorium Albuquerque School District |
| Carlsbad |
National Pot Ash Refinery Potash Company of America |
| Eunice |
Skelly Oil |
| Farmington |
Banco Plant Bloomfield Plant Chaco Plant |
| Four Corners |
Four Corners Power Plant |
| Los Cruces |
City of Los Cruces |
| Monument |
Warren Petroleum |
| Oil Center |
Oil Center Plant |
| Playas |
Phelps Dodge |
| Trinidad |
TU Electric |
Research
Cheng, Yung-sung Inhalation Dosimetry/exposure Index Of Fiber Aerosol
Grant: 1R01OH003900-01A1
Grant: 1R01OH003900-01A1
Abstract: DESCRIPTION (provided by applicant): Exposures to airborne asbestos and
man-made vitreous fibers (MMVFS) increase the incidence of lung cancer,
asbestosis, and mesothelioma. Fibers that deposit in the bronchial and alveolar
regions, subsequently translocating to the parenchyma, are thought to be
responsible for the development of these diseases. Physico-chernical properties
of fibers, including length, diameter, and durability in the lung, are major
factors in the etiology of these lung diseases. Because inhalation is the main
route of exposure, the deposition pattern in the respiratory tract as a
function of fiber dimensions is new information critical to understanding
respiratory dosimetry and defining the index of exposure for health protection
purposes. Controlled studies of fiber deposition in human volunteers are not
available because of ethical concerns. However, total and regional depositions
of inhaled fibers have been estimated from postmortem measurement, mathematical
modeling, and animal toxicity studies. Increasingly, mathematical deposition
models have been used to assess the dosimetry of inhaled MMVFS. However,
current lung dosimetric models for fibers in the human respiratory tract are
based on theoretical equations, which have not been verified with experimental
data. This proposal has three objectives: (1) to develop experimental
information on the deposition of fibrous aerosols as a function of fiber
diameter and length in realistic human respiratory tract replicas, (2) to
verify and improve the prediction of fiber dose estimate in human lungs using
both empirical data as well as a computational fluid dynamic technique, and (3)
to define,.a size-selective exposure index based on fiber penetration data.
Because lung diseases caused by inhaled fibers occur in the bronchial,
alveolar, and parachymal regions, a thoracic fraction defined as the fraction
of particles penetrating the larynx and reaching the lung must be established
and will be defined from experimental data obtained in this study. This
research will generate essential information on the dosimetry of inhaled fibers
in the human lung, data for an improved mathematical lung deposition model, and
a definition of the thoracic fraction of fibers for exposure assessment.
Sampling devices based on this size-selection definition can be developed in
the future for improved assessment of worker exposure.
Tags: Aerosol, Environmental Exposure, Lung Injury, Occupational Health /safety, Particle, Pulmonary Respiration Air Pollution, Asbestos, Bronchus, Fluidity, Irritation /irritant, Lung Neoplasm, Mathematical Model, Mesothelioma, Occupational Hazard, Pollution Related Respiratory Disorder, Respiratory Airway Clearance, Respiratory Hypersensitivity, Respiratory Toxin, Statistics /biometry Radiation Dosage, Respiratory Airflow Measurement, Transmission Electron Microscopy
Tags: Aerosol, Environmental Exposure, Lung Injury, Occupational Health /safety, Particle, Pulmonary Respiration Air Pollution, Asbestos, Bronchus, Fluidity, Irritation /irritant, Lung Neoplasm, Mathematical Model, Mesothelioma, Occupational Hazard, Pollution Related Respiratory Disorder, Respiratory Airway Clearance, Respiratory Hypersensitivity, Respiratory Toxin, Statistics /biometry Radiation Dosage, Respiratory Airflow Measurement, Transmission Electron Microscopy
- Followup Grant: 5R01OH003900-03
- Followup Grant: 5R01OH003900-04
- Followup Grant: 5R01OH003900-05
Clinical Trials
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Condition: Malignant Pleural Mesothelioma; MPM; Solid Tumors
Intervention: Drug: pemetrexed, cisplatin and CBP501; Drug: pemetrexed and cisplatin
More Information
Intervention: Drug: pemetrexed, cisplatin and CBP501; Drug: pemetrexed and cisplatin
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: doxorubicin hydrochloride; Drug: ranpirnase
More Information
Intervention: Drug: doxorubicin hydrochloride; Drug: ranpirnase
More Information
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: Liposomal doxorubicin; Drug: Cisplatin
More Information
Intervention: Drug: Liposomal doxorubicin; Drug: Cisplatin
More Information
Have questions about mesothelioma?
If you want answers right now call our Mesothelioma Resource Specialist - Abby Palmer, MSW.
She takes calls throughout the day and early evening. Her number is: 619-261-7922.
She is not a doctor and does not provide medical advice.
DISCLAIMER: Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly Inc. All of the information provided on this website is for informational purposes only. Neither Cancer Monthly nor this website renders medical advice or professional services. The information provided by Abby Palmer or any other employee or contractor of Cancer Monthly, Inc. is not to be considered medical advice and is not intended to replace consultation with a qualified medical professional. You should consult a qualified health care provider for medical advice and answers to personal health questions. The responsibility of your disease management plan is with your treating physicians and you should only follow your treating physician’s advice. DO NOT change or modify your disease management plan on your own without consulting your treating physicians. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website. Some information may be out of date. The information on this website is intended to convey general information only. It should not be construed as legal advice or opinion. This website and its contents are not intended to create an attorney-client relationship. You should not act on or rely on any information on this website without seeking the advice of an attorney. You are encouraged to promptly speak to legal counsel to identify and protect your legal rights and any deadlines for filing a claim or lawsuit. People who request a free book may be called to verify their address and to introduce other mesothelioma resources that are available.